Template:Cellulitis antibiotics - Revision history

Danbot: Add pediatric outpatient and inpatient dosing sections

2026-03-20T12:51:28Z

Add pediatric outpatient and inpatient dosing sections

← Older revision		Revision as of 12:51, 20 March 2026
Line 6:		Line 6:
	***Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=DS 1 tab PO BID\|context=Outpatient, MRSA\|link=no}} if MRSA suspected		***Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=DS 1 tab PO BID\|context=Outpatient, MRSA\|link=no}} if MRSA suspected
	**{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=450mg PO TID\|context=Outpatient}} covers Strep and Staph		**{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=450mg PO TID\|context=Outpatient}} covers Strep and Staph



			====Pediatric Outpatient====
			*{{AntibioticDose\|disease=Cellulitis\|drug=Cephalexin\|dose=25-50mg/kg/day PO divided q6-8h (max 500mg/dose)\|context=Pediatric Outpatient\|population=Pediatric}} '''OR'''
			**Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=8-12mg/kg/day (TMP) PO divided BID\|context=Pediatric Outpatient, MRSA\|population=Pediatric\|link=no}} if MRSA suspected
			*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=30-40mg/kg/day PO divided TID (max 1.8g/day)\|context=Pediatric Outpatient\|population=Pediatric}}

	====Inpatient====		====Inpatient====
Line 12:		Line 19:
	*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=600mg IV q12hrs\|context=Inpatient}} '''OR'''		*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=600mg IV q12hrs\|context=Inpatient}} '''OR'''
	*{{AntibioticDose\|disease=Cellulitis\|drug=Daptomycin\|dose=4mg/kg IV once daily\|context=Inpatient}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Daptomycin\|dose=4mg/kg IV once daily\|context=Inpatient}}


			====Pediatric Inpatient====
			*{{AntibioticDose\|disease=Cellulitis\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=10-13mg/kg IV q8hrs (max 900mg/dose)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=<12yr: 10mg/kg IV q8hrs; >12yr: 600mg IV q12hrs\|context=Pediatric Inpatient\|population=Pediatric}}

	====Saltwater related cellulitis====		====Saltwater related cellulitis====

Danbot: Strip translate tags to enable SMW subobject creation

2026-03-20T02:54:14Z

Strip translate tags to enable SMW subobject creation

← Older revision		Revision as of 02:54, 20 March 2026
Line 1:		Line 1:
	~~<noinclude><languages/></noinclude>~~
	~~<translate>~~
	~~<!--T:1-->~~
	''Tailor antibiotics by regional antibiogram''		''Tailor antibiotics by regional antibiogram''

	====Outpatient====		====Outpatient====
	~~<!--T:2-->~~
	*5 day treatment duration		*5 day treatment duration
	**{{AntibioticDose\|disease=Cellulitis\|drug=Cephalexin\|dose=500mg PO q6hrs\|context=Outpatient}} '''OR'''		**{{AntibioticDose\|disease=Cellulitis\|drug=Cephalexin\|dose=500mg PO q6hrs\|context=Outpatient}} '''OR'''
Line 12:		Line 8:

	====Inpatient====		====Inpatient====
	~~<!--T:3-->~~
	*{{AntibioticDose\|disease=Cellulitis\|drug=Vancomycin\|dose=20mg/kg IV q12hrs\|context=Inpatient}} '''OR'''		*{{AntibioticDose\|disease=Cellulitis\|drug=Vancomycin\|dose=20mg/kg IV q12hrs\|context=Inpatient}} '''OR'''
	*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=600mg IV q8hrs\|context=Inpatient}} '''OR'''		*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=600mg IV q8hrs\|context=Inpatient}} '''OR'''
Line 19:		Line 14:

	====Saltwater related cellulitis====		====Saltwater related cellulitis====
	~~<!--T:4-->~~
	*{{AntibioticDose\|disease=Cellulitis\|drug=Doxycycline\|dose=100mg PO/IV q12hrs daily\|context=Saltwater}} + [[Cefepime]] 1g IV q12hrs x 10 days		*{{AntibioticDose\|disease=Cellulitis\|drug=Doxycycline\|dose=100mg PO/IV q12hrs daily\|context=Saltwater}} + [[Cefepime]] 1g IV q12hrs x 10 days
	*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=400mg IV q12hrs x 10 days\|context=Saltwater}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=400mg IV q12hrs x 10 days\|context=Saltwater}}

	====Freshwater related cellulitis====		====Freshwater related cellulitis====
	~~<!--T:5-->~~
	*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=500mg PO q12hrs x 10 days\|context=Freshwater}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=500mg PO q12hrs x 10 days\|context=Freshwater}}
	*{{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=2 DS tablets PO q12hrs x 10 days\|context=Freshwater}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=2 DS tablets PO q12hrs x 10 days\|context=Freshwater}}
	*{{AntibioticDose\|disease=Cellulitis\|drug=Ceftriaxone\|dose=1g (50mg/kg) IV q24hrs\|context=Freshwater}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Ceftriaxone\|dose=1g (50mg/kg) IV q24hrs\|context=Freshwater}}
	~~</translate>~~

Danbot: Convert to AntibioticDose with disease=Cellulitis

2026-03-20T01:09:13Z

Convert to AntibioticDose with disease=Cellulitis

← Older revision		Revision as of 01:09, 20 March 2026
Line 2:		Line 2:
	<translate>		<translate>
	<!--T:1-->		<!--T:1-->
	''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''Tailor antibiotics by regional antibiogram''

	====Outpatient==== <!--T:2-->		====Outpatient====
			<!--T:2-->
			*5 day treatment duration
			**{{AntibioticDose\|disease=Cellulitis\|drug=Cephalexin\|dose=500mg PO q6hrs\|context=Outpatient}} '''OR'''
			***Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=DS 1 tab PO BID\|context=Outpatient, MRSA\|link=no}} if MRSA suspected
			**{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=450mg PO TID\|context=Outpatient}} covers Strep and Staph

			====Inpatient====
	<!--T:3-->		<!--T:3-->
	''~~Coverage primarily for [[Special:MyLanguage/Strep~~\|~~Strep]]~~''~~<br~~ />		*{{AntibioticDose\|disease=Cellulitis\|drug=Vancomycin\|dose=20mg/kg IV q12hrs\|context=Inpatient}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=600mg IV q8hrs\|context=Inpatient}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=600mg IV q12hrs\|context=Inpatient}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Daptomycin\|dose=4mg/kg IV once daily\|context=Inpatient}}

			====Saltwater related cellulitis====
	<!--T:4-->		<!--T:4-->
	~~''[[Special:MyLanguage/MRSA~~\|~~MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV~~ drug ~~use, or SIRS''<ref name~~="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		*{{AntibioticDose\|disease=Cellulitis\|drug=Doxycycline\|dose=100mg PO/IV q12hrs daily\|context=Saltwater}} + [[Cefepime]] 1g IV q12hrs x 10 days
	*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name=~~"IDSA guidelines" />~~		*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=400mg IV q12hrs x 10 days\|context=Saltwater}}
	**[[Special:MyLanguage/Cephalexin\|Cephalexin]] 500mg PO ~~q6hrs '''OR'''~~
	***Add [[Special:MyLanguage/~~TMP/SMX~~\|TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[~~Special:MyLanguage/MRSA\|MRSA~~]] ~~is suspected~~
	***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
	**[[Special:MyLanguage/Clindamycin\|~~Clindamycin]] 450mg PO TID covers both Strep and Staph~~
	**Tetracyclines (like [[Special:MyLanguage/Doxycycline\|Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10~~-20.</ref>~~

			====Freshwater related cellulitis====
	====~~Inpatient~~==== <!--T:5~~-->~~		<!--T:5-->
			*{{AntibioticDose\|disease=Cellulitis\|drug=Ciprofloxacin\|dose=500mg PO q12hrs x 10 days\|context=Freshwater}}
	~~<!--T:6~~-->		*{{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=2 DS tablets PO q12hrs x 10 days\|context=Freshwater}}
	*~~[[Special:MyLanguage/Vancomycin~~\|~~Vancomycin]] 20mg/kg IV q12hrs '''OR'''~~		*{{AntibioticDose\|disease=Cellulitis\|drug=Ceftriaxone\|dose=1g (50mg/kg) IV q24hrs\|context=Freshwater}}
	*[[Special:MyLanguage/Clindamycin\|~~Clindamycin]] 600mg IV q8hrs '''OR'''~~
	*[[Special:MyLanguage/Linezolid\|Linezolid]] 600mg IV q12hrs '''OR'''
	*[[Special:MyLanguage/Daptomycin\|~~Daptomycin]] 4mg/kg IV once daily~~


	=~~===Saltwater related cellulitis==== <!--T:7-->~~

	~~<!--T:8-->~~
	~~''coverage extended for [[Special:MyLanguage/Vibrio vulnificus\|Vibrio vulnificus]]''~~
	*[[Special:MyLanguage/Doxycycline\|Doxycycline]] 100mg PO~~/IV q12hrs daily + [[Special:MyLanguage/Cefepime\|Cefepime]] 1g IV~~ q12hrs x 10 days
	*[[Special:MyLanguage/Ciprofloxacin\|~~Ciprofloxacin]] 400mg IV q12hrs x 10 days~~
	*~~[[Special:MyLanguage/Ciprofloxacin~~\|~~Ciprofloxacin]] 750mg PO q12hrs x 10 days~~


	==~~==Freshwater related cellulitis==== <!~~-~~-T:9-->~~

	~~<!--T:10-->~~
	~~''coverage extended for [[Special:MyLanguage/Aeromonas sp~~\|~~Aeromonas sp]]''~~
	*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 400mg IV q12hrs x 10 days
	*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 500mg PO q12hrs x 10 days
	*[[Special:MyLanguage/TMP/SMX\|~~TMP/SMX]]~~ 2 DS tablets ~~(5mg/kg)~~ PO q12hrs x 10 days
	*~~[[Special:MyLanguage/~~Ceftriaxone\|~~Ceftriaxone]]~~ 1g (50mg/kg) IV q24hrs
	</translate>		</translate>

Ostermayer: Marked this version for translation

2026-01-27T15:58:54Z

Marked this version for translation

← Older revision		Revision as of 15:58, 27 January 2026
Line 1:		Line 1:
	<noinclude><languages/></noinclude>		<noinclude><languages/></noinclude>
	<translate>		<translate>
			<!--T:1-->
	''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>

	====Outpatient====		====Outpatient==== <!--T:2-->

			<!--T:3-->
	''Coverage primarily for [[Special:MyLanguage/Strep\|Strep]]''<br />		''Coverage primarily for [[Special:MyLanguage/Strep\|Strep]]''<br />

			<!--T:4-->
	''[[Special:MyLanguage/MRSA\|MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''[[Special:MyLanguage/MRSA\|MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>
	*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />		*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />
Line 16:		Line 19:


	====Inpatient====		====Inpatient==== <!--T:5-->

			<!--T:6-->
	*[[Special:MyLanguage/Vancomycin\|Vancomycin]] 20mg/kg IV q12hrs '''OR'''		*[[Special:MyLanguage/Vancomycin\|Vancomycin]] 20mg/kg IV q12hrs '''OR'''
	*[[Special:MyLanguage/Clindamycin\|Clindamycin]] 600mg IV q8hrs '''OR'''		*[[Special:MyLanguage/Clindamycin\|Clindamycin]] 600mg IV q8hrs '''OR'''
Line 24:		Line 28:


	====Saltwater related cellulitis====		====Saltwater related cellulitis==== <!--T:7-->

			<!--T:8-->
	''coverage extended for [[Special:MyLanguage/Vibrio vulnificus\|Vibrio vulnificus]]''		''coverage extended for [[Special:MyLanguage/Vibrio vulnificus\|Vibrio vulnificus]]''
	*[[Special:MyLanguage/Doxycycline\|Doxycycline]] 100mg PO/IV q12hrs daily + [[Special:MyLanguage/Cefepime\|Cefepime]] 1g IV q12hrs x 10 days		*[[Special:MyLanguage/Doxycycline\|Doxycycline]] 100mg PO/IV q12hrs daily + [[Special:MyLanguage/Cefepime\|Cefepime]] 1g IV q12hrs x 10 days
Line 32:		Line 37:


	====Freshwater related cellulitis====		====Freshwater related cellulitis==== <!--T:9-->

			<!--T:10-->
	''coverage extended for [[Special:MyLanguage/Aeromonas sp\|Aeromonas sp]]''		''coverage extended for [[Special:MyLanguage/Aeromonas sp\|Aeromonas sp]]''
	*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 400mg IV q12hrs x 10 days		*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 400mg IV q12hrs x 10 days

Ostermayer at 15:58, 27 January 2026

2026-01-27T15:58:21Z

← Older revision		Revision as of 15:58, 27 January 2026
Line 1:		Line 1:
	<languages/>		<noinclude><languages/></noinclude>
	<translate>		<translate>
	''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>

Ostermayer: Prepared the page for translation

2026-01-27T15:57:46Z

Prepared the page for translation

← Older revision		Revision as of 15:57, 27 January 2026
Line 1:		Line 1:
			<languages/>
			<translate>
	''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''Tailor antibiotics by regional antibiogram''<ref>Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>

	====Outpatient====		====Outpatient====
	~~''Coverage primarily for [[Strep]]''<br />~~

	''[[MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''Coverage primarily for [[Special:MyLanguage/Strep\|Strep]]''<br />

			''[[Special:MyLanguage/MRSA\|MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>
	*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />		*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />
	**[[Cephalexin]] 500mg PO q6hrs '''OR'''		**[[Special:MyLanguage/Cephalexin\|Cephalexin]] 500mg PO q6hrs '''OR'''
	***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected		***Add [[Special:MyLanguage/TMP/SMX\|TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[Special:MyLanguage/MRSA\|MRSA]] is suspected
	***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>		***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
	**[[Clindamycin]] 450mg PO TID covers both Strep and Staph		**[[Special:MyLanguage/Clindamycin\|Clindamycin]] 450mg PO TID covers both Strep and Staph
	**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>		**Tetracyclines (like [[Special:MyLanguage/Doxycycline\|Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>


	====Inpatient====		====Inpatient====
	*[[Vancomycin]] 20mg/kg IV q12hrs '''OR'''
	*[[Clindamycin]] 600mg IV q8hrs '''OR'''		*[[Special:MyLanguage/Vancomycin\|Vancomycin]] 20mg/kg IV q12hrs '''OR'''
	*[[Linezolid]] 600mg IV q12hrs '''OR'''		*[[Special:MyLanguage/Clindamycin\|Clindamycin]] 600mg IV q8hrs '''OR'''
	*[[Daptomycin]] 4mg/kg IV once daily		*[[Special:MyLanguage/Linezolid\|Linezolid]] 600mg IV q12hrs '''OR'''
			*[[Special:MyLanguage/Daptomycin\|Daptomycin]] 4mg/kg IV once daily


	====Saltwater related cellulitis====		====Saltwater related cellulitis====
	''coverage extended for [[Vibrio vulnificus]]''
	*[[Doxycycline]] 100mg PO/IV q12hrs daily + [[Cefepime]] 1g IV q12hrs x 10 days		''coverage extended for [[Special:MyLanguage/Vibrio vulnificus\|Vibrio vulnificus]]''
	*[[Ciprofloxacin]] 400mg IV q12hrs x 10 days		*[[Special:MyLanguage/Doxycycline\|Doxycycline]] 100mg PO/IV q12hrs daily + [[Special:MyLanguage/Cefepime\|Cefepime]] 1g IV q12hrs x 10 days
	*[[Ciprofloxacin]] 750mg PO q12hrs x 10 days		*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 400mg IV q12hrs x 10 days
			*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 750mg PO q12hrs x 10 days


	====Freshwater related cellulitis====		====Freshwater related cellulitis====
	''coverage extended for [[Aeromonas sp]]''
	*[[Ciprofloxacin]] 400mg IV q12hrs x 10 days		''coverage extended for [[Special:MyLanguage/Aeromonas sp\|Aeromonas sp]]''
	*[[Ciprofloxacin]] 500mg PO q12hrs x 10 days		*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 400mg IV q12hrs x 10 days
	*[[TMP/SMX]] 2 DS tablets (5mg/kg) PO q12hrs x 10 days		*[[Special:MyLanguage/Ciprofloxacin\|Ciprofloxacin]] 500mg PO q12hrs x 10 days
	*[[Ceftriaxone]] 1g (50mg/kg) IV q24hrs		*[[Special:MyLanguage/TMP/SMX\|TMP/SMX]] 2 DS tablets (5mg/kg) PO q12hrs x 10 days
			*[[Special:MyLanguage/Ceftriaxone\|Ceftriaxone]] 1g (50mg/kg) IV q24hrs
			</translate>

Spenceemmett: /* Outpatient */

2018-09-14T16:49:26Z

Outpatient

← Older revision		Revision as of 16:49, 14 September 2018
Line 8:		Line 8:
	***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected		***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected
	***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>		***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
	**[[Clindamycin]] 450mg PO TID covers both ~~strep~~ and ~~staph.~~		**[[Clindamycin]] 450mg PO TID covers both Strep and Staph
	**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>		**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>

Spenceemmett: /* Outpatient */

2018-09-14T16:48:41Z

Outpatient

← Older revision		Revision as of 16:48, 14 September 2018
Line 8:		Line 8:
	***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected		***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected
	***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>		***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
	**[[Clindamycin]] 450mg PO TID		**[[Clindamycin]] 450mg PO TID covers both strep and staph.
	**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>		**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>

Spenceemmett: /* Outpatient */

2018-09-14T16:47:52Z

Outpatient

← Older revision		Revision as of 16:47, 14 September 2018
Line 7:		Line 7:
	**[[Cephalexin]] 500mg PO q6hrs '''OR'''		**[[Cephalexin]] 500mg PO q6hrs '''OR'''
	***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected		***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected
	***Most cases of non-purulent cellulitis are ~~thought~~ caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>		***Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
	**[[Clindamycin]] 450mg PO TID		**[[Clindamycin]] 450mg PO TID
	**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis, due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>		**Tetracyclines (like [[Doxycycline]]) should be avoided in non-purulent cellulitis due to high rates of Strep resistance<ref>Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.</ref>

	====Inpatient====		====Inpatient====

Mholtz at 21:04, 6 July 2017

2017-07-06T21:04:37Z

← Older revision		Revision as of 21:04, 6 July 2017
Line 5:		Line 5:
	''[[MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>		''[[MRSA]] coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS''<ref name="IDSA guidelines">Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52</ref>
	*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />		*5 day treatment duration, unless symptoms do not improve within that timeframe<ref name="IDSA guidelines" />
	**[[Cephalexin]] 500mg PO q6hrs OR		**[[Cephalexin]] 500mg PO q6hrs '''OR'''
	***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected		***Add [[TMP/SMX]] DS 1 tab PO BID<ref>Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.</ref> if [[MRSA]] is suspected
	***Most cases of non-purulent cellulitis are thought caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>		***Most cases of non-purulent cellulitis are thought caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.<ref>Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762</ref>
Line 12:		Line 12:

	====Inpatient====		====Inpatient====
	*[[Vancomycin]] 20mg/kg IV q12hrs OR		*[[Vancomycin]] 20mg/kg IV q12hrs '''OR'''
	*[[Clindamycin]] 600mg IV q8hrs OR		*[[Clindamycin]] 600mg IV q8hrs '''OR'''
	*[[Linezolid]] 600mg IV q12hrs OR		*[[Linezolid]] 600mg IV q12hrs '''OR'''
	*[[Daptomycin]] 4mg/kg IV once daily		*[[Daptomycin]] 4mg/kg IV once daily

← Older revision		Revision as of 12:51, 20 March 2026
Line 6:		Line 6:
	***Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=DS 1 tab PO BID\|context=Outpatient, MRSA\|link=no}} if MRSA suspected		***Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=DS 1 tab PO BID\|context=Outpatient, MRSA\|link=no}} if MRSA suspected
	**{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=450mg PO TID\|context=Outpatient}} covers Strep and Staph		**{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=450mg PO TID\|context=Outpatient}} covers Strep and Staph



			====Pediatric Outpatient====
			*{{AntibioticDose\|disease=Cellulitis\|drug=Cephalexin\|dose=25-50mg/kg/day PO divided q6-8h (max 500mg/dose)\|context=Pediatric Outpatient\|population=Pediatric}} '''OR'''
			**Add {{AntibioticDose\|disease=Cellulitis\|drug=Trimethoprim-Sulfamethoxazole DS\|display=TMP/SMX\|dose=8-12mg/kg/day (TMP) PO divided BID\|context=Pediatric Outpatient, MRSA\|population=Pediatric\|link=no}} if MRSA suspected
			*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=30-40mg/kg/day PO divided TID (max 1.8g/day)\|context=Pediatric Outpatient\|population=Pediatric}}

	====Inpatient====		====Inpatient====
Line 12:		Line 19:
	*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=600mg IV q12hrs\|context=Inpatient}} '''OR'''		*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=600mg IV q12hrs\|context=Inpatient}} '''OR'''
	*{{AntibioticDose\|disease=Cellulitis\|drug=Daptomycin\|dose=4mg/kg IV once daily\|context=Inpatient}}		*{{AntibioticDose\|disease=Cellulitis\|drug=Daptomycin\|dose=4mg/kg IV once daily\|context=Inpatient}}


			====Pediatric Inpatient====
			*{{AntibioticDose\|disease=Cellulitis\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Clindamycin\|dose=10-13mg/kg IV q8hrs (max 900mg/dose)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Cellulitis\|drug=Linezolid\|dose=<12yr: 10mg/kg IV q8hrs; >12yr: 600mg IV q12hrs\|context=Pediatric Inpatient\|population=Pediatric}}

	====Saltwater related cellulitis====		====Saltwater related cellulitis====